RBC Competitors

Stocks . Taiwan . 
Stock . RBC Bioscience
6848 Stock   16.50  0.30  1.79%   
RBC Bioscience competes with Feng Chi, Visgeneer, IXensor, UniPharma, and EPS Bio; as well as few others. Analyzing RBC Bioscience competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of RBC Bioscience to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

RBC Bioscience vs 4170 Correlation

Good diversification

The correlation between RBC Bioscience and 4170 is -0.07 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding RBC Bioscience and 4170 in the same portfolio, assuming nothing else is changed.

Moving against RBC Stock

  0.772882 Cathay Financial HoldingPairCorr
  0.671303 Nan Ya PlasticsPairCorr
  0.62454 MediaTek Earnings Call This WeekPairCorr
  0.592330 Taiwan SemiconductorPairCorr
  0.570050 YuantaP shares TaiwanPairCorr

RBC Bioscience Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between RBC Bioscience and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of RBC and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of RBC Bioscience does not affect the price movement of the other competitor.

High positive correlations

6549
+ 0.72
6621
4183
+ 0.66
4197
6662
+ 0.5
4197
6662
+ 0.5
4183
7607
+ 0.48
6744
6549
+ 0.48
4197
  

High negative correlations

4183
- 0.48
7607
6621
- 0.47
6744
7607
- 0.45
4197
4183
- 0.38
6744
4197
- 0.36
6744
4170
- 0.33
4197

Risk-Adjusted Indicators

There is a big difference between RBC Stock performing well and RBC Bioscience Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze RBC Bioscience's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
6744  1.16 (0.33) 0.00 (0.77) 0.00 
 0.00 
 2.34 
(4.39)
 7.84 
4197  1.41  0.08  0.01 (0.44) 1.83 
(2.42)
 4.35 
(4.23)
 10.00 
6734  4.98  1.21  0.13  4.52  6.91 
(6.65)
 6.36 
(5.44)
 20.89 
6621  1.39  0.10  0.04  0.21  1.80 
(1.63)
 2.81 
(2.54)
 9.14 
7607  1.90 (0.28) 0.00  6.03  0.00 
 0.00 
 3.24 
(4.65)
 14.41 
4183  0.99 (0.24) 0.00 (0.77) 0.00 
 0.00 
 2.56 
(2.35)
 6.53 
6797  2.49  0.25  0.05 (0.67) 3.36 
(2.98)
 8.73 
(7.10)
 22.74 
6662  0.89 (0.06) 0.00  0.68  0.00 
 0.00 
 2.14 
(1.72)
 5.46 
6549  1.41  0.15  0.07  1.59  1.40 
(1.94)
 3.77 
(2.74)
 8.00 
4170  2.27  0.00  0.00  0.03  0.00 
 0.00 
 4.44 
(3.81)
 19.83 

RBC Bioscience Competitive Analysis

The better you understand RBC Bioscience competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, RBC Bioscience's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across RBC Bioscience's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
6848 6744 4197 6734 6621 7607 4183 6797 6662 6549
 1.79 
 16.50 
RBC
 4.91 
 16.45 
Feng
 2.97 
 10.40 
Visgeneer
 44.59 
 9.89 
IXensor
 5.20 
 12.75 
UniPharma
 2.78 
 17.50 
7607
 0.92 
 16.15 
EPS
 4.52 
 16.90 
Taiwan
 0.16 
 30.50 
BioLASCO
 1.70 
 8.11 
TaiwanJ
Market Volatility
(90 Days Market Risk)
Not too volatile
Not too volatile
Not too volatile
Risky
Not too volatile
Not too volatile
Very steady
Somewhat reliable
Very steady
Not too volatile
Market Performance
(90 Days Performance)
Weakest
Weakest
Weakest
Fair
Mild
Weakest
Weakest
Soft
Weakest
Mild
Odds of Financial Distress
(Probability Of Bankruptcy)
Unknown
Low
Moderate
High
Low
Unknown
Low
Low
Low
High
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Sell
Strong Sell
Strong Sell
Strong Hold
Strong Sell
Cautious Hold
Strong Sell
Sell
Hold
Current Ratio
N/A
4.64
N/A
4.71
9.6
N/A
2.88
2.62
7.75
14.77
Net Asset
N/A
N/A
427.04 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Profit Margin
N/A
14.19
0.0251
N/A
-39.93
N/A
9.33
33.89
19.91
-237.97
EBITDA
N/A
35.77 M
19.19 M
(92.19 M)
(15.17 M)
N/A
46.92 M
809.69 M
69.58 M
10.42 M
Operating Margin
N/A
15.98
-0.0208
-696.46
-14.87
N/A
7.56
40.21
23.75
-16.9
Current Valuation
N/A
214.9 M
388.73 M
737.24 M
286.35 M
N/A
345.41 M
945.75 M
595.07 M
641.12 M
Price To Book
N/A
1.66
1.39
9.15
1.23
N/A
1.36
1.34
1.68
4.23
Beta
N/A
N/A
0.64
0.99
1.18
N/A
1.3
N/A
0.44
0.27
Number Of Employees
N/A
31
13
N/A
42
N/A
121
N/A
79
16
Shares Outstanding
N/A
15.4 M
30.18 M
49.41 M
35.2 M
N/A
23.8 M
23.17 M
25.61 M
69.2 M
Cash Flow From Operations
N/A
39.28 M
12.34 M
(70.8 M)
(17.18 M)
N/A
37.37 M
789.25 M
73.88 M
10.53 M
Total Debt
N/A
5.26 M
170 M
3.8 M
16.82 M
N/A
141.01 M
553.23 M
70.63 M
477 K
Return On Equity
N/A
11.58
0.0162
-89.84
-14.19
N/A
14.88
50.59
11.09
-58.57
Z Score
N/A
42.6
1.2
N/A
16.2
N/A
1.2
1.2
6.6
N/A
Return On Asset
N/A
6.48
-0.0043
-52.32
-2.96
N/A
4.42
19.95
6.41
-2.5
Book Value Per Share
N/A
14.62
7.49
1.6
10.77
N/A
12.43
44.83
18.39
2.6
Total Asset
N/A
N/A
427.04 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Debt To Equity
N/A
0.023
N/A
0.047
0.044
N/A
47.6
0.35
0.15
0.2
Last Dividend Paid
N/A
1.15
N/A
N/A
N/A
N/A
0.7
6.0
2.0
N/A
Market Capitalization
N/A
374.22 M
372.74 M
723.78 M
464.65 M
N/A
402.22 M
1.39 B
792.69 M
741.16 M
Price To Earning
N/A
14.82
N/A
N/A
N/A
N/A
9.74
1.98
15.25
N/A
Price To Sales
N/A
2.09
2.12
51.55
3.35
N/A
0.9
0.74
3.06
12.01
Net Income
N/A
25.39 M
820 K
(89.69 M)
(55.35 M)
N/A
41.47 M
636.96 M
51.55 M
(146.88 M)
Earnings Per Share
N/A
1.64
0.12
-1.55
-1.57
N/A
1.74
30.37
2.03
-2.14
Shares Owned By Insiders
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
47.69
N/A
Revenue
N/A
178.91 M
165.29 M
14.04 M
138.64 M
N/A
444.68 M
1.88 B
258.98 M
61.72 M
Cash And Equivalents
N/A
219.26 M
N/A
31.28 M
188.09 M
N/A
202.58 M
1.37 B
263.13 M
100.1 M
Cash Per Share
N/A
14.24
N/A
0.6
5.34
N/A
8.51
45.56
10.27
1.45
Gross Profit
N/A
85.92 M
67.27 M
4.5 M
69.32 M
N/A
95.71 M
1.07 B
130.29 M
N/A
Day Typical Price
16.55
16.45
10.23
11.95
12.9
17.48
16.25
16.83
30.5
8.04
Accumulation Distribution
0.0209
N/A
0.049
0.6
0.0634
0.042
0.0182
0.1
0.0227
0.0488
Market Facilitation Index
0.35
N/A
0.51
11.05
0.85
0.75
0.3
1.8
0.7
0.4
Daily Balance Of Power
(0.86)
0
0.5882
(0.72)
(0.82)
(0.67)
(0.50)
(0.44)
(0.07)
(0.35)
Period Momentum Indicator
(0.30)
(0.85)
0.3
(7.96)
(0.70)
(0.50)
(0.15)
(0.80)
(0.05)
(0.14)
Rate Of Daily Change
0.98
0.95
1.03
0.55
0.95
0.97
0.99
0.95
1.0
0.98
Day Median Price
16.58
16.45
10.15
12.98
12.98
17.48
16.3
16.8
30.5
8.0
Price Action Indicator
(0.22)
(0.43)
0.41
(7.06)
(0.58)
(0.23)
(0.23)
(0.30)
(0.03)
0.04
Relative Strength Index
45.31
N/A
57.87
56.48
N/A
N/A
39.94
55.62
47.19
N/A
Coefficient Of Variation
(2,510)
(583.58)
2642.75
1072.44
1499.94
(982.36)
(629.24)
1585.93
(2,340)
1166.31
Mean Deviation
1.27
1.16
1.41
4.98
1.39
1.9
0.9872
2.49
0.8862
1.41
Jensen Alpha
(0.09)
(0.33)
0.0792
1.21
0.1008
(0.28)
(0.24)
0.2457
(0.06)
0.1529
Total Risk Alpha
(0.17)
(0.40)
(0.03)
0.5812
0.0261
(0.42)
(0.30)
0.0469
(0.12)
0.0626
Sortino Ratio
N/A
N/A
0.0124
0.1342
0.0388
N/A
N/A
0.0474
N/A
0.071
Downside Variance
N/A
N/A
9.67
77.63
4.93
N/A
N/A
17.58
N/A
2.92
Standard Deviation
1.82
1.76
2.2
13.16
1.97
2.7
1.39
3.86
1.16
1.94
Kurtosis
0.5593
1.48
0.5866
21.83
1.38
1.89
1.6
2.3
0.0177
0.3425
Potential Upside
3.2
2.34
4.35
6.36
2.81
3.24
2.56
8.73
2.14
3.77
Treynor Ratio
(1.17)
(0.77)
(0.44)
4.52
0.2087
6.03
(0.77)
(0.67)
0.6773
1.59
Maximum Drawdown
8.53
7.84
10.0
20.89
9.14
14.41
6.53
22.74
5.46
8.0
Variance
3.33
3.11
4.86
173.15
3.86
7.28
1.92
14.92
1.34
3.76
Market Risk Adjusted Performance
(1.16)
(0.76)
(0.43)
4.53
0.2187
6.04
(0.76)
(0.66)
0.6873
1.6
Risk Adjusted Performance
(0.02)
(0.12)
0.0341
0.0769
0.0545
(0.07)
(0.11)
0.0537
(0.03)
0.0683
Skewness
(0.07)
(1.08)
(0.11)
3.34
(0.05)
0.5554
0.2472
0.4043
0.2271
0.5644
Semi Deviation
N/A
N/A
1.83
6.91
1.8
N/A
N/A
3.36
N/A
1.4
Information Ratio
(0.06)
(0.20)
0.0174
0.0898
0.0438
(0.12)
(0.19)
0.0514
(0.08)
0.0626
Value At Risk
(3.37)
(4.39)
(4.23)
(5.44)
(2.54)
(4.65)
(2.35)
(7.10)
(1.72)
(2.74)
Expected Short fall
N/A
N/A
(2.42)
(6.65)
(1.63)
N/A
N/A
(2.98)
N/A
(1.94)
Downside Deviation
N/A
N/A
3.11
8.81
2.22
N/A
N/A
4.19
N/A
1.71
Semi Variance
N/A
N/A
3.35
47.76
3.22
N/A
N/A
11.3
N/A
1.96

RBC Bioscience Competition Performance Charts

Five steps to successful analysis of RBC Bioscience Competition

RBC Bioscience's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by RBC Bioscience in relation to its competition. RBC Bioscience's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of RBC Bioscience in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact RBC Bioscience's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to RBC Bioscience, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your RBC Bioscience position

In addition to having RBC Bioscience in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Hybrid Mix Funds Thematic Idea Now

Hybrid Mix Funds
Hybrid Mix Funds Theme
Funds or Etfs that are made of portfolios of stocks, bonds, or cash instruments with different maturity horizons and characteristics. The Hybrid Mix Funds theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hybrid Mix Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for RBC Stock Analysis

When running RBC Bioscience's price analysis, check to measure RBC Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RBC Bioscience is operating at the current time. Most of RBC Bioscience's value examination focuses on studying past and present price action to predict the probability of RBC Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RBC Bioscience's price. Additionally, you may evaluate how the addition of RBC Bioscience to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY